1082-21-9

Basic information

• Product Name: 1,10-Phenanthroline-5-carbonitrile
• Synonyms: 1,10-Phenanthroline-5-carbonitrile
• CAS NO: 1082-21-9
• Molecular Formula: C13H7N3
• Molecular Weight: 205.21478
• Mol File: 1082-21-9.mol
• Article Data: 4

Chemical Properties

• Melting Point: 212-213 °C
• Boiling Point: 445.3±25.0 °C(Predicted)
• Appearance: /
• Density: 1.33±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 3.69±0.10(Predicted)
• CAS DataBase Reference: 1,10-Phenanthroline-5-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1,10-Phenanthroline-5-carbonitrile(1082-21-9)
• EPA Substance Registry System: 1,10-Phenanthroline-5-carbonitrile(1082-21-9)

Safety Data

• Hazardous Substances Data: 1082-21-9(Hazardous Substances Data)

Usage

General Description

1,10-Phenanthroline-5-carbonitrile is a chemical compound with the molecular formula C14H8N2. It is a derivative of phenanthroline, containing a carbonitrile functional group. 1,10-Phenanthroline-5-carbonitrile is used in various applications in the field of chemistry and materials science, including as a ligand in coordination chemistry, organic synthesis, and as a building block for the preparation of other organic compounds. Its unique structure and properties make it a valuable tool for researchers and scientists in a wide range of disciplines.

Upstream product

• 66-71-7 1,10-Phenanthroline 
• 65115-91-5 5,6-epoxy-5,6-dihydro-[1,10]phenanthroline 
• 65379-77-3 5,6-epoxy-5,6-dihydroxy-1,10-phenanthroline 
• 40000-20-2 5-bromo-1,10-phenanthroline 

Downstream Products

• 630067-06-0 1,10-phenanthroline-5-carboxylic acid 

Relevant articles and documents

Dual mechanism of action of 5-Nitro-1,10-phenanthroline against mycobacterium tuberculosis

New chemotherapeutic agents with novel mechanisms of action are urgently required to combat the challenge imposed by the emergence of drug-resistant mycobacteria. In this study, a phenotypic whole-cell screen identified 5-nitro-1,10-phenanthroline (5NP) as a lead compound. 5NP-resistant isolates harbored mutations that were mapped to fbiB and were also resistant to the bicyclic nitroimidazole PA-824. Mechanistic studies confirmed that 5NP is activated in an F420-dependent manner, resulting in the formation of 1,10-phenanthroline and 1,10-phenanthrolin-5-amine as major metabolites in bacteria. Interestingly, 5NP also killed naturally resistant intracellular bacteria by inducing autophagy in macrophages. Structure-activity relationship studies revealed the essentiality of the nitro group for in vitro activity, and an analog, 3-methyl-6-nitro-1,10-phenanthroline, that had improved in vitro activity and in vivo efficacy in mice compared with that of 5NP was designed. These findings demonstrate that, in addition to a direct mechanism of action against Mycobacterium tuberculosis, 5NP also modulates the host machinery to kill intracellular pathogens.

ANTI-CANCER LEUCIN-RICH PEPTIDES AND USES THEREOF

The invention relates to a pharmaceutically acceptable composition for use in the treatment of cancer, the composition comprising one or more peptides having a sequence comprising the motif GLLxLLxLLLxAAG, wherein x is independently selected from arginine (R), histidine (H), lysine (K), aspartic acid (D) or glutamic acid (E), and one or more pharmaceutically acceptable excipients. The invention also relates to the peptides of the pharmaceutically acceptable composition, a kit comprising the pharmaceutically acceptable composition, nucleotides encoding the peptides and vectors expressing the peptides.